Lam Research (NASDAQ:LRCX) Price Target Raised to $120.00 at Cantor Fitzgerald

Lam Research (NASDAQ:LRCX) had its price objective raised by Cantor Fitzgerald from $115.00 to $120.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have an overweight rating on the semiconductor company’s stock.

A number of other equities analysts have also weighed in on the stock. Barclays set a $83.00 price objective on shares of Lam Research and gave the company an “equal weight” rating in a research report on Monday, July 28th. Citigroup raised their target price on Lam Research from $108.00 to $113.00 and gave the company a “buy” rating in a report on Friday, August 1st. TD Cowen raised their target price on Lam Research from $100.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, July 31st. Erste Group Bank assumed coverage on Lam Research in a report on Thursday, August 14th. They issued a “buy” rating for the company. Finally, B. Riley restated a “buy” rating and issued a $115.00 price target (up previously from $95.00) on shares of Lam Research in a research report on Wednesday, June 18th. Twenty investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.30.

Lam Research Stock Performance

NASDAQ:LRCX opened at $98.41 on Thursday. The firm’s fifty day moving average price is $98.20 and its 200 day moving average price is $84.45. Lam Research has a 1-year low of $56.32 and a 1-year high of $108.02. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.21 and a quick ratio of 1.55. The firm has a market cap of $124.55 billion, a price-to-earnings ratio of 23.66, a price-to-earnings-growth ratio of 1.29 and a beta of 1.65.

Lam Research (NASDAQ:LRCX) last posted its quarterly earnings data on Wednesday, July 30th. The semiconductor company reported $1.33 earnings per share for the quarter, beating analysts’ consensus estimates of $1.21 by $0.12. Lam Research had a net margin of 29.07% and a return on equity of 58.17%. The firm had revenue of $5.17 billion for the quarter, compared to analyst estimates of $4.99 billion. During the same period last year, the firm posted $1.03 EPS. Lam Research’s quarterly revenue was up 33.6% on a year-over-year basis. Lam Research has set its Q1 2026 guidance at 1.100-1.300 EPS. On average, sell-side analysts expect that Lam Research will post 3.71 EPS for the current year.

Institutional Trading of Lam Research

A number of large investors have recently made changes to their positions in the stock. IMG Wealth Management Inc. acquired a new position in shares of Lam Research in the second quarter valued at approximately $26,000. Howard Hughes Medical Institute acquired a new position in shares of Lam Research in the second quarter valued at approximately $27,000. Strategic Wealth Investment Group LLC acquired a new position in shares of Lam Research in the second quarter valued at approximately $29,000. Delos Wealth Advisors LLC acquired a new position in shares of Lam Research in the second quarter valued at approximately $30,000. Finally, REAP Financial Group LLC acquired a new position in shares of Lam Research in the second quarter valued at approximately $31,000. Institutional investors and hedge funds own 84.61% of the company’s stock.

About Lam Research

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.